Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Trial record 1 of 2 for:    "Nephrosclerosis"
Previous Study | Return to List | Next Study

TRK-100STP Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

This study has been completed.
Sponsor:
Collaborator:
Astellas Pharma Inc
Information provided by (Responsible Party):
Toray Industries, Inc
ClinicalTrials.gov Identifier:
NCT01090037
First received: March 8, 2010
Last updated: October 2, 2014
Last verified: October 2014
  Purpose

In Chronic Renal Failure (CRF) patients with primary glomerular disease or nephrosclerosis as the primary disease:

  • To confirm the superiority of TRK-100STP over placebo
  • To determine the recommended therapeutic dose in the 2 doses of TRK-100STP
  • To assess the safety of TRK-100STP

Condition Intervention Phase
Chronic Renal Failure
Glomerular Disease
Nephrosclerosis
Drug: TRK-100STP high dose
Drug: TRK-100STP low dose
Drug: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: TRK-100STP PhaseIIb/III Clinical Study - Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)

Resource links provided by NLM:


Further study details as provided by Toray Industries, Inc:

Primary Outcome Measures:
  • Renal composite endpoints [Time to first occurrence of one of the following events:] [ Time Frame: 2-4 year ] [ Designated as safety issue: Yes ]

    (i) Doubling of SCr: Doubling of SCr is defined as a two-fold or greater increase in the SCr level, as compared with the baseline value

    (ii) ESRD (Occurrence of any of i-iii) i) Introduction of dialysis ii) Renal transplantation iii) Increase in SCr to 6.0 mg/dL or higher



Enrollment: 892
Study Start Date: March 2010
Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TRK-100STP Drug: TRK-100STP high dose Drug: TRK-100STP low dose
Placebo Comparator: Placebo Drug: Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • The CRF patient with primary glomerular disease or nephrosclerosis as the primary disease
  • The patient with progressive CRF

Exclusion Criteria:

  • The patient with secondary glomerular disease
  • The patient with CRF caused by pyelonephritis, interstitial/tubular nephritis, gouty kidney, polycystic kidney disease, or nephroureterolithiasis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01090037

Locations
China
Beijing, China
Hong Kong
Hong Kong, Hong Kong
Japan
Tokyo, Japan
Korea, Republic of
Seoul, Korea, Republic of
Malaysia
Kuala Lumpur, Malaysia
Taiwan
Taipei, Taiwan
Thailand
Bangkok, Thailand
Sponsors and Collaborators
Toray Industries, Inc
Astellas Pharma Inc
  More Information

No publications provided by Toray Industries, Inc

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Toray Industries, Inc
ClinicalTrials.gov Identifier: NCT01090037     History of Changes
Other Study ID Numbers: 100CRS02/533-CL-003
Study First Received: March 8, 2010
Last Updated: October 2, 2014
Health Authority: Japan: Pharmaceuticals and Medical Devices Agency
South Korea: Korea Food and Drug Administration (KFDA)
Taiwan: Department of Health
Hong Kong: Department of Health
China: Food and Drug Administration
Malyasia:Ministry of Health
Thailand:Thai Food and Drug Administration

Keywords provided by Toray Industries, Inc:
ESRD
Chronic Renal Failure
Prostaglandin
Prostacyclin
Asian Multinational Study

Additional relevant MeSH terms:
Nephrosclerosis
Kidney Failure, Chronic
Renal Insufficiency
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Beraprost
Cardiovascular Agents
Hematologic Agents
Pharmacologic Actions
Platelet Aggregation Inhibitors
Therapeutic Uses
Vasodilator Agents

ClinicalTrials.gov processed this record on November 27, 2014